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Purpose: This paper presents an assessment of an automated and personalized stochastic
targeted (STAR) glycemic control protocol compliance in Malaysian intensive care unit
(ICU) patients to ensure an optimized usage.
Patients and Methods: STAR proposes 1–3 hours treatment based on individual insulin
sensitivity variation and history of blood glucose, insulin, and nutrition. A total of 136
patients recorded data from STAR pilot trial in Malaysia (2017–quarter of 2019*) were used
in the study to identify the gap between chosen administered insulin and nutrition interven-
tion as recommended by STAR, and the real intervention performed.
Results: The results show the percentage of insulin compliance increased from 2017 to first
quarter of 2019* and fluctuated in feed administrations. Overall compliance amounted to
98.8% and 97.7% for administered insulin and feed, respectively. There was higher average
of 17 blood glucose measurements per day than in other centres that have been using STAR,
but longer intervals were selected when recommended. Control safety and performance were
similar for all periods showing no obvious correlation to compliance.
Conclusion: The results indicate that STAR, an automated model-based protocol is posi-
tively accepted among the Malaysian ICU clinicians to automate glycemic control and the
usage can be extended to other hospitals already. Performance could be improved with
several propositions.
Keywords: compliance, glycemic control, diabetes, stochastic targeted prediction, model-
based control
Introduction
Intensive care unit (ICU) patients are predisposed to stress hyperglycemia due to
insulin resistance arising from the initial insult.1–3 It is associated with increased
risks of multiple organ failures, sepsis, and mortality.4–7 Glycemic control (GC) has
been used to reduce hyperglycemia and mortality.8–11 However, other studies were
unable to produce the same results.12,13 Only one study reduced both mortality and
hypoglycemia,11 where increased hypoglycemic risk was an independent risk factor
for increased mortality.14,15
Glycemic control in the ICU becomes more challenging when there is a transi-
tion of conventional therapy using manual insulin treatment towards automated
personalized treatments. For example, a “one size fits all method” or ad-hoc insulin
therapy normally used as GC guidelines for fast clinical decision but the GC
treatment may not necessarily effective, productive or cost-saving.16,17 As each
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patient is different, the clinical treatment needed could be
different, and patient’s safety is also counted for GC
primary consideration. Whereas manual insulin therapy
or ad-hoc protocols used in the ICU patients need to rely
on “one size fits all method” for clinical judgement rather
than patient-specific variability.18 Thus, if more advanced
technologies treatment is used for an effective GC, all of
the challenges rise need to be countered.
Recent studies have shown safe, effective control for
almost all patients is critical to improve outcomes,19–21
validating other analyses showing time in band is associated
with survival.22–26 For better, more personalised control,
fixed insulin protocols have been replaced by automated
patient-specific model-based glycemic control.17,27-32 The
stochastic targeted (STAR), in particular, is focused on
using patient-specific time-varying insulin sensitivity33 to
provide safe, effective control to essentially all patients with
reduced workload and increased nutrition delivery.34–37
STAR uses a well-validated physiological model38 and a
user-friendly interface designed for accuracy39,40 to dose
insulin based on risk of future changes in insulin
sensitivity (SI),
41,42 an approach proven to generalise across
adult37,43 and neonatal ICUs,44–46 as well as with other
technologies.47,48 This protocol was adopted in Malaysia29
after successful studies internationally.27,31,37,49 Initial
assessment of the first Malaysian pilot trial showed the
control was safe. However, the percentage of blood glucose
(BG) within the Malaysian target band of 6.0–10.0 mmol/L
(108–180 mg/dL) was 60.7%, which is much lower than
expected50 and lower than in other studies with lower target
bands and equal safety in other countries.37
Despite very positive feedback from clinicians through
a survey conducted at the International Islamic University
Malaysia Medical Centre (IIUMMC) using the protocol,51
this paper presents a compliance analysis to identify the
level of clinician adherence to STAR protocol recommen-
dations. The assessment covers three years of patient data
using STAR, covering compliance to insulin and nutrition
recommendations.
Methods
Retrospective data from 170 IIUMMC patients (equivalent to
349 episodes of glycemic control) in the general ICU from
2017 to 2019* were retrieved from the STAR cloud database.
The data in 2019* were used until the first quarter of 2019.
Collected patients' data have received IIUMMC consent under
ethics IREC 657 and Malaysian National Institute of Health
(NIH). Patient diagnosis was unavailable for now in this study
due to incomplete overall data.
A patient can have multiple episodes of STAR GC if
control was stopped and then restarted, which happens when
patients meet stopping criteria but re-develop hyperglycemia,
or when patients leave the ICU for surgery or imaging, to name
a few possibilities. From 349 episodes, 78 episodes were
excluded because there were only 1–2 BG points and were
too short for assessment. As a result, there were 136 patients
(271 episodes) with 12,153 total hours of data analysed. A total
of 67 (49.2%) and 69 (50.8%) were male and female patients.
Table 1 shows the median and interquartile range of patient’s
age, height, and length of glycemic control (LGC), separated
into the 3 years analysed. The number of patients were the
lowest in 2019* as data were up only until April. Analysis of
Variance (ANOVA) comparison scores on age (P=0.58),
weight (P=0.62), LGC (P=0.97), and Acute Physiological
and Chronic Health (APACHE) (P=0.87) II score show no
significant difference between the three years data.




Years of Data 2017 2018 2019*
Total patients (Total patients





100 (37) 135 (76) 36 (23)
Age (years old) [Median
(Interquartile Range)]




64 [55–71] 61 [53–72] 65 [58–74]















16 [11–23] 15 [11–20] Not
available
Note: *Indicates that the available data used were until April, a quarter of 2019
unlike in the year of 2017 and 2018.
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STAR Protocol in Malaysia
STAR is implemented in tablets that record all historical
data, from all measurements, recommendations, to all cho-
sen treatments performed. It was launched in a newly
operated university hospital IIUMMC in mid-January
2017 with three tablets. At IIUMMC, the BG control
target range was 6.0–10.0 mmol/L (108–180 mg/dL)
instead of a tighter and lower BG target of 4.4–
8.0 mmol/L (79–144 mg/dL) used elsewhere.28 It provides
1-hour, 2-hour, or 3-hour treatment option recommenda-
tions for both insulin and nutrition delivery, modulating
both inputs for control.
The STAR protocol implementation framework in
Malaysia includes:
STAR starts when BG measurements were more than
10.0 mmol/L (180 mg/dL) for two consecutive hours.
STAR stops when BG measurements were stable for
five to six hours defined as not receiving more than 2 U
insulin for three consecutive BG measurement intervals
below 10.0 mmol/L.
The default insulin band given in STAR was 0.0–8.0
U/hr with allowable increments of +0.5 U to +2 U.
IIUMMC can manually modify the proposed insulin with
highest insulin given capped at 10 U/hr. Modifications are
recorded in STAR. Nutrition was provided with a non-
protein goal of 20–25 kcal/g/day and protein supplied to
be at least 1.2–1.5 g/kg/day.52 Differences in nutrition
given from the selected recommendation are recorded in
STAR by attending clinical staff.
Compliance Assessment
STAR provides up to three different recommendations
from which to choose the next interval’s insulin and nutri-
tion input. Any modification made by clinicians were
recorded in STAR. Compliance is assessed to identify
clinical adherence to the model-based protocol recommen-
dations. In this case, compliance is assessed by the number
of time clinician’s follow the dose/amount of the chosen
recommendation, quantified:
Compliance ¼ Nb: of complied interventions
Total Nb: of interventions
(1)
Compliance was assessed for each year (2017, 2018,
2019*). ANOVA test was assessed between the compli-
ance and non-compliance interventions in three different
years where p-value less than 0.05 suggests the statistical
difference. Per-patient compliance is illustrated through a
single CDF graph each, to study the level or magnitude of
non-compliance and its trends. Compliance needs to be
assessed and audited from time to time since compliance
may impact GC performances.1,18 Moreover, given STAR
is a clinical practice change, shifting from a sliding-scale
to a model-based protocol, it is interesting to see whether
the level of trust increases over the years. The magnitude
and extent of non-compliance can also provide insight into
the reasons for specific clinical choices and/or the lack of
trust in new protocol.53
Associated Performances and Safety
Performance and safety assess control quality by year and
thus if compliance influences patient control performance
outcomes. Cumulative distribution frequency plots (CDF)
of BG for three years and overall are plotted where gly-
cemic variabilities for per-patient can be referred. Median,
interquartile range, and ANOVA test were assessed
between the three different years to show the performance
and safety results statistical difference. Specific metrics
assessed include:
● Performance: Percentage of time in targeted bands
(TIB); 4.4–8.0 mmol/L (79–144 mg/dL) and 6.0–
10.0 mmol/L (108–180 mg/dL). The first target
band was chosen based on default and proposed
STAR target band.22–26 The second was the band
used in IIUMMC based on the standard Malaysian
ICU protocol.52 Clinical trial BG, insulin, and feed
were also assessed.
● Safety: Percentage of BG>10.0 mmol/L (180 mg/dL)
(hyperglycemia), BG<4.4 mmol/L (79 mg/dL),
BG<4.0 mmol/L (72 mg/dL) (mild hypoglycemia), and
BG<2.2 mmol/L (39 mg/dL) (severe hypoglycemia).
Results
Table 2 shows compliance assessment results for insulin
and nutrition administration. Overall average compliance
was 98.8% and 97.7% for insulin and nutrition, respec-
tively. Administered insulin compliance increased by 2.5%
from 97.2% in 2017 to 99.7% in 2018 and 2019*.
Compliance to nutrition recommendations was relatively
constant but fluctuating with 98.6%, 96.7%, and 98.8% for
the three years, respectively. Table 2 also shows the clin-
ical trial’s glycemic control and intervention results. The
insulin and nutrition administered were similar across the
three years. Relative to compliance, total insulin adminis-
tered was lower than recommended, but far closer in
2019* than in the first year, 2017. Workload, measured
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as number of BG measurements, averaged 17 per day
across all three years, indicating nurses were selecting
shorter treatment intervals than offered. The statistical
test between compliance and non-compliance for insulin
and feed interventions as shown in Table 2 is significantly
different where all the p-values were less than 0.05.
In terms of the performance and safety, the median BG
was a relatively constant 8.8 mmol/L to 8.6 mmol/L to
8.8 mmol/L, in all three years. Per-patient % BG between
4.4–8.0 mmol/L in 2017 and 6.0–10.0 mmol/L in 2019*
varied reflecting small shifts in control or patients, but
variations were not large, where the p-value test showed
in Table 2 are not statistically significant. Mild hypogly-
cemia fluctuated across years, but the overall hypoglyce-
mia cases is lower than 1% which shows STAR
personalized care improved hypo cases over the years.
Hyperglycemia rate for %BG > 10.0 mmol/L was
relatively constant between 16–20% of measurements,
and showed no significant different . Figure 1 shows all
per-patient BG CDF plots and the median (dotted line),
IQR of 25% to 75% (dark blue range), and 5% to 95%
(light blue range) of per-patient responses for each year
and overall, where 2017 and 2018 are qualitatively similar
and 2019* is narrower. Overall, performance was similar,
and hypoglycemia cases decreased over years. Thus, com-
pliance which was relatively high does not appear to affect
GC results in this case.
Figure 2 shows example patient episodes for Patient 68
(Compliant patient) and Patient 8 (Non-compliant patient).
Patient 68’s compliance for administered insulin and nutrition
was 100%, while Patient 8 was 73.6% (insulin) and 98.75%
(nutrition), showing potential significant reluctance to use
insulin for fear of hypoglycemia. Another example of patient
11 (referring to Figure 2C) shows compliance of insulin and
Table 2 Results of Compliance and Clinical Trials of IIUMMC Patients
Parameter Overall 2017 2018 2019 P-value Test
Insulin compliance (%) 98.8 97.2 99.7 99.7 P<0.05
Nb. of times for insulin non-compliance 109 96 10 3
Nb. episodes with insulin non-compliance 32 22 7 3
Total amount of recommended insulin (U) 24097.8 9390.6 10903.7 3485 No significant
Total amount insulin given (U) 23533.0 9162.6 10878.8 3475.7
Absolute amount of insulin non-compliance (U) 277.8 227.1 41.1 9.3
Feed compliance (%) 97.7 98.6 96.7 98.8 P<0.05
Nb. of times for feed non-compliance 200 50 136 14
Nb. episodes with feed non-compliance 66 22 39 5
Total amount of recommended feed (mL) 282493.3 122342.0 128537.0 31614.3 No significant
Total amount feed given (mL) 281142.3 121880.0 127911.0 31351.3
Absolute amount of feed non-compliance (mL) 6124.2 715 3755.1 303.0
Clinical BG in median [IQR] (mmol/L) 8.7 [7.0–11.0] 8.8 [7.0–11.0] 8.6 [6.9–10.9] 8.8 [7.1–11.0] <0.05
Clinical insulin in median [IQR] (U/hr) 1.5 [0.4–3.1] 1.6 [0.5–3.2] 1.5 [0.2–3.0] 1.5 [0.4–3.2] <0.05
Clinical feed in median [IQR] (g/hr) 5.2 [3.7–6.9] 5.2 [3.8–6.3] 5.1 [2.4–7.1] 5.2 [4.3–6.1] <0.05
Nb. of BG measurement 8777 3498 4070 1209 No significant
Average BG measurement per day 17 18 17 17 –
Hourly Resampled Measurements
%BG within 4.4–8.0 mmol/L (79–144 mg/dL) 45.0 [26.3–62.5] 50.0 [29.7–68.7] 42.7 [23.2–58.8] 43.1 [29.3–61.8] No significant
%BG within 6.0–10.0 mmol/L (108–180 mg/dL) 65.0 [50.0–78.4] 64.2 [51.1–77.7] 65.6 [47.2–78.4] 68.9 [50.6–77.6] No significant
%BG >10.0 mmol/L (180 mg/dL) 19.0 [10.6–33.9] 16.9 [10.0–30.1] 20.0 [10.7–36.4] 21.4 [15.5–38.9] No significant
%BG <4.4 mmol/L (79 mg/dL) 0.0 [0.0–1.4] 0.0 [0.0–3.7] 0.0 [0.0–0.9] 0.0 [0.0–0.0] <0.05
%BG <4.0 mmol/L (72 mg/dL) mild hypoglycemia 0.830 1.313 0.530 0.574 <0.05
%BG <2.2 mmol/L (39 mg/dL) 0.0 [0.0–0.0] No significant
Nb. episodes of mild hypoglycemia 93 38 45 10 –
Nb. episodes of severe hypoglycemia 2 1 1 0 –
Abbreviations: Nb, number; BG, blood glucose.
Abdul Razak et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Medical Devices: Evidence and Research 2020:13142
Figure 1 BG cumulative distribution frequency (CDF) for (A) Overall (B) 2017 (C) 2018 and (D) 2019*.
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Figure 2 Profile figures of (A) compliant episode (patient 68), and (B) non-compliant episode (Patient 8) under STAR protocol. The first panel represents blood glucose
(BG) mmol/L. The cross (x) is the BG clinical reading and the line is fitted BG using integral fitting method. The dashed line represents the BG limit target of 6–10.0 mmol/L
(108–180 mg/dL). The second panel shows the plasma insulin (I) mU/L (dashed line) and interstitial insulin (Q) mU/L (straight line). The third panel is patient’s insulin
sensitivity and the last panel represents insulin administered and feed given, straight line for insulin (U/hr), dashed line for Enteral feed (g/hr), and dashed dotted line for
Parenteral feed (g/hr).
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nutrition was 39.2% and 98%. Patient 8 and 11 had lesser GC
performance and higher BG values, indicating compliance
percentage below 80% for insulin interventions did affect
both patients, and those other patients with significant non-
compliance were similar. The BG, insulin, and feed interven-
tions between compliant and non-compliant showed in Table 2
are statistically different where the p-value was less than 0.05.
However, the clinical difference is not evident in the overall
cohort.
Figures 3 and 4 show the per-episode non-compliant
amount of insulin and nutrition for each year. These fig-
ures illustrate the difference between selected recommen-
dation and the real amount given, summed in total.
Negative values mean the amount given was more than
recommended. 2018 has the highest nutrition non-compli-
ance amount (700.4 mL for Patient 5) and rate of occur-
rence. For insulin, 2017 is the most non-compliant year by
rate of occurrence, and Patient 11 had the distinctive case
Figure 3 Non-compliance nutrition amount (mL) per episode for each year. It is clear non-compliance occurs primarily in 2017–18 .
Figure 4 Non-compliance in total recommended insulin amount (U) per episode for each year. It is clear non-compliance occurs primarily in 2017 .
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with a difference of 57.4 U, noting a significant under-
dosing compared to recommended values and treatments
selected. Notably, insulin non-compliance is all under-dos-
ing (positive values) in Figure 4, where there is some
spread in Figure 3 for nutrition administration.
Table 3 summarizes the availability and the number of
times 1-hour, 2-hour, or 3-hour interval interventions were
chosen, in three contexts, i) only option 1-hour available,
ii) only option 1-hour and 2-hours available, and iii) All 3
options available.
Discussion
Overall, the results show good compliance where clin-
icians followed STAR recommendations even though it
was a major change in practice. The comparison
between the compliance and non-compliance interven-
tions for both insulin (P=5.4 x 10−15) and nutrition
(P=0) demonstrated statistical difference with p-values
less than 0.05. In particular, compliance to dosing
recommendations increased over the years. In addition,
the level of non-compliance seen in the rate of occur-
rence per-patient and amount or magnitude of difference
fell. Insulin compliance was more notable, and always
an under-dosing compared to recommendation, reflect-
ing a well-known fear of hypoglycemia.53–55
In-contrast, non-compliance to nutrition recommenda-
tions was slightly more common, and in most cases repre-
sented increases to meet a certain standard. There is a need
to scrutinize these episodes in particular to consolidate the
ICU’s nutrition guidelines and goals more clearly,56
including correlation with glycemic control performance
as STAR has been shown to be able to provide world-best
nutrition delivery, in practice as well as in (fully compli-
ant) virtual trials.35,36 STAR control provides balance in
insulin and nutrition automated clinical care treatment. In
this study, the percentage of compliance interventions was
high which demonstrated the acceptance of transition in
automated technology and personalized treatment.
Workload was higher than other cases internationally
with 17 measurements per day versus 12 per day in other
centres.37 The issue is that there were far fewer times where
longer intervals were offered. They were highly selected
when they were offered, as seen in Table 3. The issue is the
short length of episodes compared to other centres and high
initial BG values meaning there was a lower time in band, as
noted in Table 2, and higher proportion of hyperglycemia
(Table 2) than other centres.37 These results ensure that there
is a greater proportion of 1-hour only options available in
control, where longer stay allows patients to be more stably
controlled and thus longer options to be chosen. This issue
might be better addressed by considering any of a lower
target band, as per other centres,37 a more difficult stopping
criteria requiring BG under 8.0 mmol/L and low insulin
dosing for stopping instead of BG < 10.0 mmol/L as now,
and/or earlier commencement where initial high BG values
make control workload harder as longer intervals are not
available until BG is in the goal band. These
considerations require further study and consultation with
clinical staff, although clinically validated virtual trials
show the potential.34,43,50,57-62
Finally, except for improving compliance, specifically
in insulin delivery, there was no clear pattern across the
years. This result clearly shows the STAR protocol was
taken up and that confidence in its insulin dosing rose over
time with nursing and clinical staff. It also demonstrates
the consistency in control quality seen in studies across
other centres.37 Both outcomes are positive for the proto-
col in general.
This study has at least 2 limitations. First, important
details pertaining to patient demographics and diagnoses,
such as morbidities and type of ICU admission are not
available for now as we only have these data on the ear-
liest 30 patients thus were not included for this study. As a
result, a more in-depth study on possible root causes for
non-compliance cannot be made, nor can non-compliance
be associated with a particular patient type of diagnosis
Table 3 The Availability and Number of Times 1-, 2-, and 3-Hour Interval Interventions Chosen
BG Treatment Recommended Total BG Treatment Recommended Number of Chosen/Available BG Treatment
1-Hour 2-Hours 3-Hours
Only Option 1 Recommended 277 277/277
Only Options 1 and 2 Recommended 710 432/571 136/139
Options 1, 2, and 3 Recommended 11919 5676/7930 818/2353 1395/1636
Total and Overall Percentage 12906 6385/8778 954/2492 1395/1636
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group. In addition, as noted, results are influenced by the
relatively short length of patient episode on GC. Instead of
grouping data by years, a study with patients/episodes
grouped by length of stay and length of glycemic control
in the ICU might be more informative. Equally, a further
study considering stopping criteria that administered insu-
lin longer could reduce the effect of having multiple short
episodes in lieu of a single longer episode per patient as is
more common in other centres.37
Conclusion
The STAR protocol was well accepted at IIUMMC as a
new model-based control protocol to replace a fixed insu-
lin therapy approach. Compliance analysis showed high
compliance to insulin and nutrition administration recom-
mendations of over ~96%. These values were relatively
constant over the three years considered, but increased for
insulin showing increasing confidence in the protocol over
time, although initial levels were very high. Control safety
and performance were similar for all periods and overall
were acceptable, showing no noticeable impact of compli-
ance. Performance could be improved with a range of
options from different target bands to changed stopping
criteria that required more stable control performance
before stopping glycemic control. STAR is expected to
be used in other ICUs in Malaysia.
Abbreviations
GC, glycemic control; BG, blood glucose; STAR, stochastic
targeted; ICU, intensive care unit; SI, insulin sensitivity; Nb,
number; IQR, interquartile range; IIUMMC, International
Islamic University Malaysia Medical Centre.
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